Shared and separate functions of polo-like kinases and aurora kinases in cancer
The DOI matches its Crossref record; 228 of the 228 references it cites were found in a registry or an index.
Abstract
Large numbers of inhibitors for polo-like kinases and aurora kinases are currently being evaluated as anticancer drugs. Interest in these drugs is fuelled by the idea that these kinases have unique functions in mitosis. Within the polo-like kinase family, the emphasis for targeted therapies has been on polo-like kinase 1 (PLK1), and in the aurora kinase family drugs have been developed to specifically target aurora kinase A (AURKA; also known as STK6) and/or aurora kinase B (AURKB; also known as STK12). Information on the selectivity of these compounds in vivo is limited, but it is likely that off-target effects within the same kinase families will affect efficacy and toxicity profiles. In addition, it is becoming clear that interplay between polo-like kinases and aurora kinases is much more extensive than initially anticipated, and that both kinase families are important factors in the response to classical chemotherapeutics that damage the genome or the mitotic spindle. In this Review we discuss the implications of these novel insights on the clinical applicability of polo-like kinase and aurora kinase inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, some kinases and phosphatases simultaneously hit the same kinesins to tune the balance between phosphorylation and dephosphorylation to modulate activity or spindle targeting [56, 57].”
From Regulatory mechanisms that control mitotic kinesins (2015) · cites this paper as [56]
Citations
Cites
Microtubules as a target for anticancer drugs
Jordan, M. A., & Wilson, L. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1317 · Cited by 4,000 · cited 1×
“Well-known examples of these drugs are those that perturb the formation of the mitotic spindle such as taxanes and vinca alkaloids”
BackgroundEffects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967 · cited 1×
“This means that their mode of action will be different from inhibitors of the ERBB2 (also known as HER2 or neu receptor) or the breakpoint cluster region (BCR)–ABL1 oncoproteins that directly suppress oncogenic signal”
BackgroundAddiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
The anaphase promoting complex/cyclosome: a machine designed to destroy
Peters, J.-M. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1988 · Cited by 1,315 · cited 1×
“Once proper chromosome alignment is established, cyclin B and securin are degraded by the anaphase-promoting complex/cyclosome bound to CDC20 (APC/C CDC20”
BackgroundTyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene Products
Lugo, T. G., Pendergast, A.-M., Muller, A. J., & Witte, O. N. (1990) · Science · doi:10.1126/science.2408149 · Cited by 1,281 · cited 1×
“This means that their mode of action will be different from inhibitors of the ERBB2 (also known as HER2 or neu receptor) or the breakpoint cluster region (BCR)–ABL1 oncoproteins that directly suppress oncogenic signal”
BackgroundTumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation
Zhou, H., Kuang, J., Zhong, L., Kuo, W.-L., Gray, J., Sahin, A., Brinkley, B., & Sen, S. (1998) · Nature Genetics · doi:10.1038/2496 · Cited by 1,276
A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers
Bischoff, J. R. (1998) · The EMBO Journal · doi:10.1093/emboj/17.11.3052 · Cited by 1,216 · cited 1×
“Oncogenic activity Overexpression of aurora kinase A induces oncogenic transformation in immortalized rodent fibroblast”
BackgroundDitchfield, C., Johnson, V. L., Tighe, A., Ellston, R., Haworth, C., Johnson, T., Mortlock, A., Keen, N., & Taylor, S. S. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200208091 · Cited by 1,194 · cited 1×
“gov/drugdictionary/?CdrID=39762">paclitaxel (also known as Taxol)-induced mitotic arres”
BackgroundHauf, S., Cole, R. W., LaTerra, S., Zimmer, C., Schnapp, G., Walter, R., Heckel, A., van Meel, J., Rieder, C. L., & Peters, J.-M. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200208092 · Cited by 1,155 · cited 1×
“gov/drugdictionary/?CdrID=39762">paclitaxel (also known as Taxol)-induced mitotic arres”
BackgroundA Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
Luo, J., Emanuele, M. J., Li, D., Creighton, C. J., Schlabach, M. R., Westbrook, T. F., Wong, K.-K., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.05.006 · Cited by 1,017 · cited 1×
“Most recently, tumour cell lines carrying a KRAS-G13D mutation were shown to be hypersensitive to inhibition of PLK1 (Ref”
Background
Cited by
Items 201–300 of 609
Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma
Tavanti, E., Sero, V, Vella, S., Fanelli, M., Michelacci, F., Landuzzi, L., Magagnoli, G., Versteeg, R., Picci, P., Hattinger, C. M., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.643 · Cited by 38
“kinases-targeting drugs in osteosarcoma”
Greatwall and Polo-like Kinase 1 Coordinate to Promote Checkpoint Recovery
Peng, A., Wang, L., & Fisher, L. A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.257121 · Cited by 44
Louwen, F., & Yuan, J. (2013) · Oncotarget · doi:10.18632/oncotarget.1096 · Cited by 42
“Multiple small molecule inhibitors targeting the ATP-binding pocket of the kinase domain and its inactive conformation have been developed [7,33-35].”
BackgroundCisplatin‐resistant cancer cells are sensitive to Aurora kinase A inhibition by alisertib
Wang, L., Arras, J., Katsha, A. M., Hamdan, S. A., Belkhiri, A., Ecsedy, J., & El-Rifai, W. M. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12066 · Cited by 40
“Aurora kinase A (AURKA) is a serine/threonine cell cycle kinase, whose main physiological function in normal cells is related to centrosome and spindle assembly (Lens et al., 2010).”
BackgroundBorisa, A., & Bhatt, H. (2015) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2015.08.017 · Cited by 38
“Aurora-A and B are highly expressed in majority of human cancer cell lines (Lens et al., 2010).”
Backgroundp73 as a Pharmaceutical Target for Cancer Therapy
Bisso, A., Collavin, L., & Sal, G. D. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795222667 · Cited by 43
“Aurora kinase A inhibitors appear very promising among the new classes of compounds that are undergoing clinical or preclinical validation as anticancer drugs [177].”
BackgroundInvestigating cytokinesis failure as a strategy in cancer therapy
McKenzie, C., & D’Avino, P. P. (2016) · Oncotarget · doi:10.18632/oncotarget.13556 · Cited by 39
“Finally, CIT-K could be potentially targeted by small molecule inhibitors designed to interfere with its ATP binding pocket, an approach successfully used to generate inhibitors of other cell division kinases of the Aurora and Polo-like kinase families that are currently in clinical trials for the treatment of various…”
BackgroundStabilization of AURKA by the E3 ubiquitin ligase CBLC in lung adenocarcinoma
Hong, S., Lu, Y., Hsiao, S.-H., Kao, Y.-R., Lee, M.-H., Lin, Y.-P., Wang, C., & Wu, C. (2022) · Oncogene · doi:10.1038/s41388-022-02180-6 · Cited by 45
“Polo-like kinases and Aurora kinases are two essential families of mitotic kinases, which regulate centrosome maturation, kinetochore-spindle attachment, chromosome separation and cytokinesis [14].”
BackgroundCHFR: a key checkpoint component implicated in a wide range of cancers
Sanbhnani, S., & Yeong, F. M. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0892-2 · Cited by 41
“Since Plk1 and Aurora A are frequently over-expressed in certain cancers [24] and likely also in the cell-lines derived from them, this could have influenced the conclusions drawn as to the effects of CHFR on the stability of Plk1 and Aurora A observed.”
BackgroundFraedrich, K., Schrader, J., Ittrich, H., Keller, G., Gontarewicz, A., Matzat, V., Kromminga, A., Pace, A., Moll, J. K., Bläker, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2968 · Cited by 37
“tent and H3 phosphorylation were carried out by flow cytometry as described (12, 13, 18).”
MethodCentrosome – a promising anti-cancer target
Rivera-Rivera, Y., & Saavedra, H. I. (2016) · Biologics · doi:10.2147/btt.s87396 · Cited by 44
VanGenderen, C. A., Harkness, T. A. A., & Arnason, T. (2020) · Aging · doi:10.18632/aging.103792 · Cited by 39
“Polo-like kinase 1 (PLK1) is a serine/threonine kinase that is implicated in tumorigenesis and serves as a prognostic marker for worsened patient outcomes in multiple cancers, including non-small cell lung cancer (NSCLC) [201], head and neck squamous cell carcinomas [202], and breast cancer [48, 203, 204].”
BackgroundCauses of Chromosomal Instability
Bastians, H. (2015) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-20291-4_5 · Cited by 45
Yu, F., Jiang, Y. P., Lu, L., Cao, M., Qiao, Y., Liu, X., Liu, D., Dyke, T. V., Wang, F., Yao, X., et al. (2017) · Cell Discovery · doi:10.1038/celldisc.2016.49 · Cited by 37
Zhou, S.-F., Li, J.-P., Yang, Y.-X., Liu, Q., Zhou, Z.-W., Pan, S., He, Z., Zhang, X., Yang, T., Pan, S.-Y., et al. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s74412 · Cited by 36
RetractedAurora Kinase Inhibition Induces PUMA via NF-κB to Kill Colon Cancer Cells
Sun, J., Knickelbein, K., He, K., Chen, D., Dudgeon, C., Shu, Y., Yu, J., & Zhang, L. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0846 · Cited by 36
“They are frequently overexpressed in a variety of tumors and promote cell cycle progression (1).”
Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines
Baldini, E., Tuccilli, C., Prinzi, N., Sorrenti, S., Antonelli, A., Gnessi, L., Morrone, S., Moretti, C., Bononi, M., Arlot‐Bonnemains, Y., et al. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0299 · Cited by 36
“Aurora-B, togetherwith the proteins INCENP, Survivin and Borealin, is a component of the chromosomal passenger complex (CPC), which localizes along the chromosome arms in prophase, concentrates in the inner centromere region from prometaphase to metaphase, moves to the central spindle and cortex in anaphase, and remai…”
BackgroundMao, Y., Xi, L., Li, Q., Wang, S., Cai, Z., Zhang, X., & Yu, C. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.04.011 · Cited by 36
“Polo-like kinase 1(Plk1), a serine/threonine kinase that plays an essential role in cell mitosis, spindle assemble, DNA damage and so on, is amember of polo-like kinases family [5,6].”
BackgroundA urora Kinase B Is a Potential Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma
Buczkowicz, P., Zarghooni, M., Bartels, U. K., Morrison, A., Misuraca, K. L., Chan, T. S. Y., Bouffet, É., Huang, A., Becher, O. J., & Hawkins, C. E. (2012) · Brain Pathology · doi:10.1111/j.1750-3639.2012.00633.x · Cited by 36
“AURKB inhibition has been reported to cause perturbed spindle biorientation, chromosome misalignment, and induce polyploidy and micronuclei formation (19, 20).”
BackgroundSpartà, A., Bressanin, D., Chiarini, F., Lonetti, A., Cappellini, A., Evangelisti, C., Evangelisti, C., Melchionda, F., Pession, A., Bertaina, A., et al. (2014) · Cell Cycle · doi:10.4161/cc.29267 · Cited by 36
“However, both AK-A and AK-B have been associated with tumorigenesis and their overexpression is frequently observed in multiple tumor types, where it is correlated with higher grades of malignancy, higher proliferation rates, and poor prognosis.(3,6-8) Unlike AK-A and AK-B that are ubiquitously expressed in all mammal…”
BackgroundYao, R., Kondoh, Y., Natsume, Y., Yamanaka, H., Inoue, M., Toki, H., Takagi, R., Shimizu, T., Yamori, T., Osada, H., et al. (2013) · Oncogene · doi:10.1038/onc.2013.382 · Cited by 36
Su, Y., Pan, S., Li, Z., Li, L., Wu, X., Hao, P., Sze, S. K., & Yao, S. Q. (2015) · Scientific Reports · doi:10.1038/srep07724 · Cited by 35
Sharma, A. K., Madhunapantula, S. V., Gowda, R., Berg, A. S., Neves, R. I., & Robertson, G. P. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.12.019 · Cited by 38
Inhibition of Bcl-xL sensitizes cells to mitotic blockers, but not mitotic drivers
Bennett, A., Sloss, O., Topham, C. H., Nelson, L., Tighe, A., & Taylor, S. S. (2016) · Open Biology · doi:10.1098/rsob.160134 · Cited by 41
Floc’h, N., Ashton, S. E., Taylor, P., Trueman, D., Harris, E., Odedra, R., Maratea, K., Derbyshire, N. A., Caddy, J., Jacobs, V. N., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0580 · Cited by 35
“B induced chromosomemisalignments during mitosis and failed cytokinesis leading to polyploidy and eventually to cell death (17).”
BackgroundCo-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe
Li, J., Hong, M. J., Chow, J. P. H., Man, W. Y., Mak, J. P. Y., Ma, H. T., & Poon, R. Y. C. (2015) · Oncotarget · doi:10.18632/oncotarget.3313 · Cited by 35
“In addition of their mutual regulation, an emerging view is that PLK1 cooperates with Aurora kinases to regulate multiple stages of mitosis, including cohesion, centrosome maturation, and kinetochore–microtubule interaction [17].”
Contribution of Aurora-A and -B expression to DNA aneuploidy in gastric cancers
Honma, K., Nakanishi, R., Nakanoko, T., Ando, K., Saeki, H., Oki, E., Iimori, M., Kitao, H., Kakeji, Y., & Maehara, Y. (2013) · Surgery Today · doi:10.1007/s00595-013-0581-x · Cited by 36
“Several inhibitors of Aurora kinases have been clinically evaluated as anticancer drugs [14].”
BackgroundXu, L. L., Zhu, Y., Shao, J., Chen, M., Yan, H., Li, G., Zhu, Y., Xu, Z., Yang, B., Luo, P., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.55 · Cited by 37
“PLK1 is a member of a serine/threonine kinases (PLK1–4) family and highly associated with G2 checkpoint (Lens et al, 2010; Liang et al, 2014) and is widely believed to have an important role expression of PLK1 and p-4EBP1 were analysed by western blotting.”
BackgroundHuck, J. J., Zhang, M., Mettetal, J. T., Chakravarty, A., Venkatakrishnan, K., Zhou, X., Kleinfield, R., Hyer, M. L., Kannan, K., Shinde, V., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0027 · Cited by 36
“Aurora A mediates multiple steps throughout mitosis, including centrosome maturation and separation, mitotic entry, formation of mitotic spindle poles and spindles, alignment of chromosomes during metaphase and their subsequent separation during anaphase [7-11].”
BackgroundMohan, P., Castellsagué, J., Jiang, J., Allen, K. E., Chen, H., Nemirovsky, O., Spyra, M., Hu, K., Kluwe, L., Pujana, M. Á., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.793 · Cited by 35
“We sought to identify and modulate the responsible pathways behind the cytostatic effects of MLN8237 on MPNST cell-lines and focused our initial investigations on pathways that are frequently altered in cells treated with AKI, such as apoptotic cell death, arrest at the G2-M transition, endoreduplication, and replicat…”
BackgroundInfluentialWaraky, A., Akopyan, K., Parrow, V., Strömberg, T., Axelson, M., Abrahmsén, L., Lindqvist, A., Larsson, O., & Aleem, E. A. (2014) · Oncotarget · doi:10.18632/oncotarget.2292 · Cited by 35
“These processes depend on the activities of Aurora A kinase and its downstream target Plk1, which has prompted interest in their function as anticancer targets [38].”
BackgroundTNK2 gene amplification is a novel predictor of a poor prognosis in patients with gastric cancer
Shinmura, K., Kiyose, S., Nagura, K., Igarashi, H., Inoue, Y., Nakamura, S., Maeda, M., Baba, M., Konno, H., & Sugimura, H. (2013) · Journal of Surgical Oncology · doi:10.1002/jso.23482 · Cited by 36
“Since the function of AURKA is mainly related to centrosome function and spindle assembly and the overexpression of AURKA results in a defective spindle assembly checkpoint, allowing abnormal chromosomal separation and leading to aneuploidy and the induction of chromosome instability [38], such a phenomenon in gastric…”
BackgroundWissing, M. D., Mendonca, J., Kortenhorst, M. S. Q., Kaelber, N. S., Gonzalez, M., Kim, E., Hammers, H. J., van Diest, P. J., Carducci, M. A., & Kachhap, S. K. (2013) · The FASEB Journal · doi:10.1096/fj.12-222893 · Cited by 33
“During mitosis, there is extensive crosstalk between Plk1 and aurora A and B kinases, two other key regulators of mitosis (26).”
BackgroundClinical Development of Anti-mitotic Drugs in Cancer
Olziersky, A.-M., & Labidi‐Galy, S. I. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-57127-0_6 · Cited by 35
Identification of new inhibitors against human Great wall kinase using in silico approaches
Ammarah, U., Kumar, A., Pal, R. R., Bal, N. C., & Misra, G. (2018) · Scientific Reports · doi:10.1038/s41598-018-23246-0 · Cited by 34
PLK1 Inhibition Induces Immunogenic Cell Death and Enhances Immunity against NSCLC
Zhou, J. H. S., Yang, Q., Lu, L., Tuo, Z., Shou, Z., & Cheng, J. (2021) · International Journal of Medical Sciences · doi:10.7150/ijms.60135 · Cited by 38
YAP/BRD4‐controlled ROR1 promotes tumor‐initiating cells and hyperproliferation in pancreatic cancer
Yamazaki, M., Hino, S., Usuki, S., Miyazaki, Y., Oda, T., Nakao, M., Ito, T., & Yamagata, K. (2023) · The EMBO Journal · doi:10.15252/embj.2022112614 · Cited by 34
“Aurora kinase B (AURKB) plays an important role in mitotic chromosome condensation (Lens et al, 2010) and has attracted considerable interest as a potential therapeutic target because of its overexpression in several cancer tissues, such as non-small cell lung carcinoma, glioblastoma, and ovarian…”
BackgroundCheng, A., Tian, X., You, W., Wang, T., Zhang, D., Guo, H., Zhang, H., Pan, X., Wang, Y., Liu, L., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00832-9 · Cited by 32
Current and Future Trials of Targeted Therapies in Cutaneous Melanoma
Evans, M., Madhunapantula, S. V., Robertson, G. P., & Drabick, J. J. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-6176-0_10 · Cited by 35
Karlin, K. L., Mondal, G., Hartman, J. K., Tyagi, S., Kurley, S. J., Bland, C. S., Hsu, T. Y. T., Renwick, A., Fang, J. E., Migliaccio, I., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.10.011 · Cited by 34
“Because of the many described functions of PLK1 and potential pleiotropic effects of PLK1 inhibition (Lens et al., 2010; Petronczki et al., 2008), we tested this hypothesis by altering STP axis function via SCYL1 or TEX14 gain- or loss-of-function and measuring the effect on TNBC cell transformation.”
BackgroundInfluentialFanale, D., Bazan, V., Corsini, L. R., Caruso, S., Insalaco, L., Castiglia, M., Cicero, G., Bronte, G., & Russo, A. D. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2649-0 · Cited by 33
“The Aurora family kinases, especially aurora-A, play a particularly important role in the cell cycle and their deregulated expression is involved in many types of human malignancies [47, 48].”
BackgroundZhou, S.-F., Yuan, C.-X., Zhou, Z.-W., Yang, Y.-X., He, Z., Zhang, X., Qian, C., Yang, T., Pan, S.-Y., & Chen, X.-W. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s74964 · Cited by 34
“A number of Aurora kinase inhibitors have been developed, and have shown variable efficacy at different stages of preclinical and clinical trials (Ding et al, unpublished data, 2014; Yuan et al, unpublished data, 2014).(17) Danusertib (Figure 1A), formerly known as PHA-739358, is a potent pan-Aurora kinase inhibitor w…”
RetractedYang, W., Zhao, X., Han, Y., Duan, L., Lü, X., Wang, X., Zhang, Y., Zhou, W. J., Liu, J., Zhang, H., et al. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0854-6 · Cited by 34
“PLK1 was one of the most extensively studied genes in cell cycle regulation [48], and it was highly expressed in various cancers, especially in gastric cancer [49], lung cancer [50], and pancreatic carcinoma [34].”
Redox priming promotes Aurora A activation during mitosis
Lim, D., Joukov, V., Rettenmaier, T. J., Kumagai, A., Dunphy, W. G., Wells, J. A., & Yaffe, M. B. (2020) · Science Signaling · doi:10.1126/scisignal.abb6707 · Cited by 32
MASTL: A novel therapeutic target for Cancer Malignancy
Fatima, I., Singh, A. B., & Dhawan, P. (2020) · Cancer Medicine · doi:10.1002/cam4.3141 · Cited by 34
Aurora B prevents delayed DNA replication and premature mitotic exit by repressing p21Cip1
Trakala, M., Fernández‐Miranda, G., de Castro, I. P., Heeschen, C., & Malumbres, M. (2013) · Cell Cycle · doi:10.4161/cc.24004 · Cited by 41
“in mitotic progression until these defects are corrected.(4,5,10-12) Substrate phosphorylation depends on the distance of the substrate from Aurora B at the inner centromere, thus indicating that recruitment of the CPC to the kinetochore prevents the stabilization of improper attachments and activates the SAC to delay…”
BackgroundSo, C. H., Michal, A. M., Mashayekhi, R., & Benovic, J. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.353854 · Cited by 31
Treatment of Acute Myeloid Leukemia in the Era of Genomics—Achievements and Persisting Challenges
Green, S. D., & Koenig, H. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00480 · Cited by 35
“Polo-Like Kinase Polo-like kinases (PLKs) are involved in the regulation of mitosis and cellular division (Lens et al., 2010).”
BackgroundPolo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53
Sanhaji, M., Louwen, F., Zimmer, B., Kreis, N., Roth, S., & Yuan, J. (2013) · Cell Cycle · doi:10.4161/cc.24573 · Cited by 31
Valianou, M., Cox, A. M., Pichette, B., Hartley, S., Paladhi, U. R., & Astrinidis, A. (2015) · Cell Cycle · doi:10.4161/15384101.2014.986394 · Cited by 30
Casorzo, L., Dell’Aglio, C., Sarotto, I., & Risio, M. (2014) · Human Pathology · doi:10.1016/j.humpath.2014.11.016 · Cited by 30
Molecular Pathways: Regulation and Targeting of Kinetochore–Microtubule Attachment in Cancer
Herman, J., Toledo, C. M., Olson, J. M., DeLuca, J. G., & Paddison, P. J. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0645 · Cited by 35
“Conversely, in late mitosis, KT–MT attachments are stabilized to generate forces required for chromosome movements and to silence the spindle assembly checkpoint (SAC), which prevents mitotic exit until all chromosomes are properly bioriented (1, 2).”
BackgroundInfluentialEpigenetic modifying enzyme expression in asthmatic airway epithelial cells and fibroblasts
Stefanowicz, D., Ullah, J., Lee, K., Shaheen, F., Olumese, E., Fishbane, N., Koo, H.-K., Hallstrand, T. S., Knight, D. A., & Hackett, T. (2017) · BMC Pulmonary Medicine · doi:10.1186/s12890-017-0371-0 · Cited by 31
Liu, Z., Lei, Q., Wei, W., Xiong, L., Shi, Y., Yan, G., Gao, C., Ye, T., Wang, N., & Yu, L. (2017) · RSC Advances · doi:10.1039/c7ra02518a · Cited by 30
Recent progress in agents targeting polo-like kinases: Promising therapeutic strategies
Zhang, Z., Xing, X., Guan, P. F., Song, S., You, G., Xia, C., & Liu, T. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113314 · Cited by 30
Synthetic Strategies of Pyrimidine-Based Scaffolds as Aurora Kinase and Polo-like Kinase Inhibitors
Jadhav, M., Sankhe, K., Bhandare, R. R., Edis, Z., Bloukh, S. H., & Khan, T. A. (2021) · Molecules · doi:10.3390/molecules26175170 · Cited by 29
“AURK and PLK play a central role in regulating mitotic entry and progression as they are associated with centrosome maturation, mitotic spindle formation and chromosome separation [12,13].”
BackgroundDiaz, R. J., Golbourn, B. J., Faria, C. C., Picard, D. J., Shih, D. J. H., Raynaud, D., Leadly, M., Mackenzie, D., Bryant, M., Bebenek, M., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.3245 · Cited by 31
“[4] Aurora kinase B (Aurora B) is an essential serine/threonine kinase responsible for regulation of multiple events in mitosis including chromosome condensation, centromere-kinetochore dynamics, chromatid segregation, and cytokinesis.[5] One of the hallmarks of Aurora kinase B inhibition is G2/M arrest and subsequent…”
BackgroundSilva, V. C., & Cassimeris, L. (2013) · Molecular Biology of the Cell · doi:10.1091/mbc.e13-02-0108 · Cited by 34
“Reduced activation of Plk1, measured within the nucleus, could result from either loss of centrosome localization, where it is activated (Lens et al., 2010), or reduced nuclear import and/or nuclear retention of the active kinase.”
BackgroundLi, W., & Zhao, Y. (2018) · Asian Journal of Andrology · doi:10.4103/aja.aja_32_18 · Cited by 32
Drugs by Numbers: Reaction‐Driven De Novo Design of Potent and Selective Anticancer Leads
Spänkuch, B., Keppner, S., Lange, L. D., Rodrigues, T., Zettl, H., Koch, C. P., Reutlinger, M., Hartenfeller, M., Schneider, P., & Schneider, G. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201206897 · Cited by 28
Aurora kinase A interacts with H-Ras and potentiates Ras-MAPK signaling
Umstead, M., Xiong, J., Qi, Q., Du, Y., & Fu, H. (2017) · Oncotarget · doi:10.18632/oncotarget.15049 · Cited by 29
PUF60/AURKA Axis Contributes to Tumor Progression and Malignant Phenotypes in Bladder Cancer
Qian, L., An, X., Chen, M., Wang, N., Sui, S., Li, Y., Zhang, C., Lee, K., Wang, X., Tian, T., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.568015 · Cited by 28
“In the past several decades, emerging studies have proved that AURKA plays an important role in tumor development and progression (37).”
BackgroundA look into the link between centrosome amplification and breast cancer
Zhang, Y., Tian, J., Qu, C., Peng, Y., Lei, J., Sun, L., Zong, B., & Liu, S. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110924 · Cited by 31
Metselaar, D. S., du Chatinier, A., Meel, M. H., ter Huizen, G., Waranecki, P., Goulding, J. R., Bugiani, M., Köster, J., Kaspers, G. J. L., & Hulleman, E. (2022) · iScience · doi:10.1016/j.isci.2022.104398 · Cited by 29
“It is well established that AURKA and PLK1 reciprocally activate each other and cooperatively regulate multiple stages of mitosis including mitotic entry, centrosome maturation, chromosome segregation, and cytokinesis, by phosphorylating shared or specific substrates (Asteriti et al., 2015; Joukov and De Nicolo, 2018;…”
BackgroundResultGollapudi, P., Hasegawa, L. S., & Eastmond, D. A. (2014) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2014.03.004 · Cited by 28
“Similarly, overexpression of Aurora B kinase is thought play a role in chromosomal instability by interfering with chromosome biorientation and the spindle checkpoint [14].”
BackgroundTrakala, M., Partida, D., Salazar‐Roa, M., Maroto, M., Wachowicz, P., de Cárcer, G., & Malumbres, M. (2015) · Blood · doi:10.1182/blood-2015-03-634402 · Cited by 31
“Because of its critical functions in themitotic cell cycle and its expression in human tumors, Plk1 has been proposed as a cancer target, and recent clinical trialswith Plk1 inhibitors have indeed shown significant therapeutic effect in hematopoietic tumors.(15,18-21) These findings have been used to propose new thera…”
BackgroundLi, D., Fu, J., Du, M., Zhang, H., Li, L., Cen, J., Li, W., Chen, X., Lin, Y., Conway, E. M., et al. (2016) · Hepatology · doi:10.1002/hep.28637 · Cited by 28
“Polo-like kinase 1 (PLK1) and Aurora B kinase are two key kinases in regulating CPC functions.((13)) There are several highly selective compounds targeting against PLK1 or Aurora B.”
The CINs of Polo-Like Kinase 1 in Cancer
Cunningham, C. E., MacAuley, M. J., Vizeacoumar, F. S., Abuhussein, O., Freywald, A., & Vizeacoumar, F. J. (2020) · Cancers · doi:10.3390/cancers12102953 · Cited by 31
“PLK1 is a serine/threonine (Ser/Thr) protein kinase belonging to the PLK family, which overall consists of 5 kinases, PLK1 to PLK5 [29].”
BackgroundInfluentialTargetingCDKN3in cervical cancer
Berumen-Campos, J., Espinosa-García, A. M., & Medina, I. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.941808 · Cited by 27
“To resolve these issues, a new generation of antimitotic agents has been developed that target kinesins and kinases that play unique roles in mitosis, such as KIF11, PLK1 and aurora kinase A [46].”
BackgroundInvestigation of expressions of PDK 1, PLK 1 and c‐Myc in diffuse large B‐cell lymphoma
Feng, Y., Lin, J., Liu, Y., Tang, Y., Zhou, Y., & Zhong, M. (2019) · International Journal of Experimental Pathology · doi:10.1111/iep.12307 · Cited by 27
Zhou, D., Hayashi, T., Jean, M. J., Kong, W., Fiches, G. N., Biswas, A., Liu, S., Yosief, H. O., Zhang, X., Bradner, J. E., et al. (2020) · Science Advances · doi:10.1126/sciadv.aba1941 · Cited by 30
“One explanation is that pharmacological inhibition of AURKA may generate some adverse effect that compensates for their block of HIV-1–induced PLK1 elevation and prevents cell death, because AURKA is also involved in various other cellular signals (24).”
Revisiting Aurora Kinase B: A promising therapeutic target for cancer therapy
Lakkaniga, N. R., Wang, Z., Xiao, Y., Kharbanda, A., Lan, L., & Li, H. (2023) · Medicinal Research Reviews · doi:10.1002/med.21994 · Cited by 30
BRCA1 downregulates the kinase activity of Polo-like kinase 1 in response to replication stress
Zou, J., Rezvani, K. S., Wang, H., Lee, K. S., & Zhang, D. (2013) · Cell Cycle · doi:10.4161/cc.25349 · Cited by 28
“PLK1 is considered to be a potential anticancer target, and many PLK1 inhibitors are now in different stages of clinical trial.(37,38) In this study, we found that BRCA1 deficiency causes inefficient inhibition of PLK1 in response to DNA damage.”
BackgroundDiscovery of novel 2,4-disubstituted pyrimidines as Aurora kinase inhibitors
Xu, Y., Hao, S.-Y., Zhang, X., Li, W., Qiao, X.-P., Wang, Z.-X., & Chen, S. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.126885 · Cited by 27
Targeting the INCENP IN-box–Aurora B interaction to inhibit CPC activity in vivo
Gohard, F. H., St‐Cyr, D. J., Tyers, M., & Earnshaw, W. C. (2014) · Open Biology · doi:10.1098/rsob.140163 · Cited by 26
“Because of their role in promoting accurate cell division, the Aurora kinases have been actively explored as targets for chemical inhibition in the treatment of cancer [20,21].”
BackgroundSubcellular drug targeting illuminates local kinase action
Bucko, P. J., Lombard, C. K., Rathbun, L. I., Garcia, I., Bhat, A., Wordeman, L. G., Smith, F. D., Maly, D. J., Hehnly, H., & Scott, J. D. (2019) · eLife · doi:10.7554/elife.52220 · Cited by 27
“Although it is well established that Plk1 and AurA coordinate various aspects of cell division, current drug-targeting strategies limit our ability to decode the spatiotemporal regulation of these events (Barr et al., 2004; Combes et al., 2017; Lens et al., 2010).”
BackgroundIndependent Prognostic Potential of GNPNAT1 in Lung Adenocarcinoma
Zheng, X., Li, Y., Ma, C., Zhang, J., Zhang, Y., Fu, Z., & Luo, H. (2020) · BioMed Research International · doi:10.1155/2020/8851437 · Cited by 30
Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models
Davis, S. L., Robertson, K. M., Pitts, T. M., Tentler, J. J., Bradshaw‐Pierce, E. L., Klauck, P. J., Bagby, S. M., Hyatt, S. L., Selby, H. M., Spreafico, A., et al. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00120 · Cited by 26
“Aurora kinase inhibitors are a class of novel agents that disrupt the normal functions of nuclear kinases Aurora A, B, and C in spindle pole organization and mitosis leading to disruption of cell division and chromosomal abnormalities (Lens et al., 2010; Kollareddy et al., 2012).”
BackgroundCives, M., Ciavarella, S., Rizzo, F. M., Matteo, M. D., Dammacco, F., & Silvestris, F. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.01.020 · Cited by 26
Kalous, O., Conklin, D. F., Desai, A. J., Dering, J., Goldstein, J. B., Ginther, C., Anderson, L. A., Lu, M., Kolarova, T. R., Eckardt, M. A., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2702-z · Cited by 28
“More than a dozen small-molecule Aurora kinase inhibitors have been tested in clinical trials (reviewed in [19, 20]).”
BackgroundLi, N., Maly, D. J., Chanthery, Y. H., Sirkis, D. W., Nakamura, J. L., Berger, M. S., James, C. D., Shokat, K. M., Weiss, W. A., & Persson, A. I. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0526 · Cited by 27
“Therefore, AURK inhibitors represent an attractive approach to target proliferating GBM cells without affecting nondividing neurons and glial cells (42).”
BackgroundPolymeric micelles for siRNA delivery
Falamarzian, A., Xiong, X.-B., Uludag, H., & Lavasanifar, A. (2012) · Journal of Drug Delivery Science and Technology · doi:10.1016/s1773-2247(12)50004-3 · Cited by 25
Mitosis-targeting therapies: a troubleshooting guide
Doménech, E., & Malumbres, M. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.03.011 · Cited by 25
“DNA synthesis inhibitors) may provide additional benefits given the role of these kinases in the recovery process that occurs following DNA damage [10].”
BackgroundJanning, M., & Fiedler, W. (2014) · Future Oncology · doi:10.2217/fon.14.53 · Cited by 27
Álvarez‐Fernández, M., & Malumbres, M. (2014) · BioEssays · doi:10.1002/bies.201400040 · Cited by 34
“Polo-like kinase (Plk)1, the best known member of Polo kinases, plays essential roles in different processes such as centrosome maturation, mitotic entry, spindle assembly, and cytokinesis [15].”
BackgroundWu, C.-C., Ekanem, T. I., Phan, N. N., Loan, D. T. T., Hou, S.-Y., Lee, K., & Wang, C. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.49652 · Cited by 27
“Meanwhile, overexpression of Aurora-A leads to centrosome duplication, and recent reports found that Tome-1 is required for proteolysis of some protein kinases and mitotic entry [49-51].”
BackgroundB-ALL Complexity: Is Targeted Therapy Still A Valuable Approach for Pediatric Patients?
Ratti, S., Lonetti, A., Follo, M. Y., Paganelli, F., Martelli, A. M., Chiarini, F., & Evangelisti, C. (2020) · Cancers · doi:10.3390/cancers12123498 · Cited by 27
Shen, Z.-J., Hsu, P., Su, Y.-T., Yang, C.-W., Kao, L., Tseng, S., Tsai, M., & Teng, S. (2014) · Nature Communications · doi:10.1038/ncomms6312 · Cited by 29
Ahn, S. (2011) · Oncology Reports · doi:10.3892/or.2011.1496 · Cited by 25
Calcagno, A., Grassi, T., Mariuzzi, L., Marzinotto, S., Londero, A. P., Orsaria, M., Beltrami, C. A., & Marchesoni, D. (2011) · Human Reproduction · doi:10.1093/humrep/der264 · Cited by 26
“Therefore, different expression levels of Aurora B and A might be explained considering that only Aurora B kinase associates with inner centromere protein (INCENP), borealin and survivin, which have a key role in cell cycle control and apoptosis (Lens et al., 2010; Musacchio, 2010).”
BackgroundPhosphatase 1 Nuclear Targeting Subunit (PNUTS) Regulates Aurora Kinases and Mitotic Progression
Wang, F., Wang, L., Fisher, L. A., Li, C., Wang, W., & Peng, A. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0670 · Cited by 28
“PNUTS depletion disrupts the mitotic localization of the chromosomal passenger complex Upon metaphase-to-anaphase transition, the Aurora B– containing chromosomal passenger complex (CPC) relocates from anaphase chromosomes to the cell equator where it mediates mitotic exit (3, 4, 40).”
BackgroundTong, J., Luo, D., Bian, S., & Zhang, X. (2021) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2021.116235 · Cited by 28
Hartsink-Segers, S. A., Exalto, C., Allen, M., Williamson, D., Clifford, S. C., Horstmann, M. A., Caron, H. N., Pieters, R., & den Boer, M. L. (2013) · Haematologica · doi:10.3324/haematol.2013.084434 · Cited by 25
“During this, PLK1 is involved in centrosome maturation, spindle formation, chromosome alignment and cytokinesis together with Aurora kinases A and B.(4) In addition, PLK1 is able to bind p53 and inhibit its pro-apoptotic function,(5) whereas, in turn, expression of PLK1 is transcriptionally repressed by p53 upon DNA d…”
BackgroundTsykunova, G., Reikvam, H., Ahmed, A. B., Nepstad, I., Gjertsen, B. T., & Bruserud, Ø. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.668525 · Cited by 24
“2 Aurora kinase A and B in human AML The Aurora kinases directly interact with the PLKs at the molecular level during cell cycle progression [49], and their possible role as therapeutic targets in human AML has recently been reviewed [50,39,51].”
BackgroundRouquier, S., Pillaire, M., Cazaux, C., & Giorgi, D. (2014) · Disease Markers · doi:10.1155/2014/798170 · Cited by 24
“AURKAand PLK1 are upregulated in a number of cancers such as breast, oesophageal, and colorectal cancers (for review see [25, 26] and references therein).”
BackgroundInfluentialSmall molecule inhibitors in acute myeloid leukemia: from the bench to the clinic
Al-Hussaini, M., & DiPersio, J. F. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.932687 · Cited by 26
“Inhibition of AKB’s function is associated with cytokinesis defects, polyploidy and apoptosis [82].”
BackgroundChen, Y., Zhang, J., Li, D., Jiang, J., Wang, Y., & Si, S. (2016) · Oncotarget · doi:10.18632/oncotarget.13603 · Cited by 24
“Plk1 inhibitors reduce tumor proliferation, but have little effect on normal cells based on the results from mouse xenograft models [11].”
BackgroundRen, D., Fisher, L. A., Zhao, J., Wang, L., Williams, B. C., Goldberg, M. L., & Peng, A. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.778233 · Cited by 25
Tian, J. L., Tian, C., Ding, Y., Li, Z., Geng, Q., Xiahou, Z., Wang, J., Hou, W., Liao, J., Dong, M., et al. (2015) · Scientific Reports · doi:10.1038/srep08360 · Cited by 23
PLK1 inhibition dampens NLRP3 inflammasome–elicited response in inflammatory disease models
Baldrighi, M., Doreth, C., Li, Y., Zhao, X., Warner, E. F., Chenoweth, H., Kishore, K., Umrania, Y., Minde, D., Thome, S., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci162129 · Cited by 23
“PLK1 is widely studied for its role in mitosis (13, 14).”
Background
Metadata
- Authors
- Lens, S. M. A., Voest, E. E., & Medema, R. H.
- Affiliations
- University Medical Center Utrecht (NL)
- Corresponding author
- Lens, Susanne M. A.
- Medema, René H.
- Venue
- Nature Reviews Cancer
- Published
- 2010-11-24
- Volume
- 10
- Issue
- 12
- Pages
- 825-841
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1994488152
- Cited by
- 597
- References
- 227
- Citations by year
- 2026: 17 · 2025: 25 · 2024: 10 · 2023: 28 · 2022: 24 · 2021: 29 · 2020: 42 · 2019: 37 · 2018: 27 · 2017: 33 · 2016: 36 · 2015: 56 · 2014: 59 · 2013: 64 · 2012: 65
- FWCI
- 4.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- Polo-like kinase, Aurora kinases, PLK1, AURKA, Aurora B kinase, mitosis, kinase inhibitors, anticancer agents, off-target effects, chemosensitization, targeted therapy
- MeSH terms
- Polo-Like Kinase 1, Animals, Chromatids, Humans, Mitosis, Neoplasms, Proto-Oncogene Proteins, Protein Serine-Threonine Kinases, Kinetochores, Cell Cycle Proteins, Protein Kinase Inhibitors, Cytokinesis, Aurora Kinase A, Aurora Kinase B, Aurora Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.